Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

Macugen approved for neovascular AMD

Dec. 21, 2004

Alcon completes NDA filing for Retaane

Dec. 21, 2004

rEV-131 for postcataract surgery impresses in preclinical study

Dec. 20, 2004

Zylet receives FDA approval

Dec. 17, 2004

Retisert NDA accepted for review

Dec. 17, 2004

Single-use vial of Vitrase approved for use as spreading agent

Dec. 9, 2004

GenVec licenses PEDF rights for ocular diseases

Dec. 2, 2004

Putative melatonin receptor agonist promising for treatment of glaucoma

Nov. 30, 2004

Sirna-027 enters phase I study for wet AMD

Nov. 25, 2004

Merck claims prostaglandin analogues as EP4 receptor agonists for ocular and bone conditions

Nov. 24, 2004

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...